Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

New AIDS Clinical Trials Unit Study Opens

December 30, 2003

ACTG Study 5142

A study to compare the effectiveness of three regimens for the initial treatment of HIV Infection

The study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection.

Eligibility:

  • HIV positive

    Advertisement

  • Planning to start anti-HIV treatment

  • No prior antiretroviral therapy

  • 18 years old or older, men and non-pregnant women

  • HIV RNA (viral load) of 2,000 copies or above

The study will last for about three years.

Exams and lab tests provided at no cost. Only TDF, EFV, LPV/r, and d4tXR will be provided by the study.

Subjects receive $20 per study visit.

Contact Alyssa or Lori at the ACTU at (206) 731-3184.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 
See Also
Washington
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement